SCHEMBL5310060

SCHEMBL5310060

COC(=O)c1c(N)ccc([N+](=O)[O-])c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 4/20 0.47
ALDH1A1 P00352 4/20 0.47
TSHR P16473 3/20 0.47
LMNA P02545 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ABCC4 O15439 1/20 0.47
PLIN1 O60240 1/20 0.47
CACNA1F O60840 1/20 0.47
GMNN O75496 1/20 0.47
KCNK2 O95069 1/20 0.47
ABCB11 O95342 1/20 0.47
GSR P00390 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
ADORA3 P0DMS8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1584481 0.84 TSHR (0.46) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL27750330 0.83 TSHR (0.49) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL7447014 0.82 TDP1 (0.51) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL13520113 0.81 TDP1 (0.50) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL31305226 0.81 TDP1 (0.50) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL543121 0.81 TSHR (0.44) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL5309337 0.81 TSHR (0.44) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL3710523 0.81 KMT2A (0.52) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL27468580 0.81 TSHR (0.46) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL1800859 0.79 ALDH1A1 (0.51) KMT2ASMN1; SMN2MAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652154-A1 NOVEL ALPK1 INHIBITORS Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) 2025-11-26 EP disclosed
WO-2024153225-A1 NOVEL ALPK1 INHIBITORS PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) 2024-07-25 WO disclosed
CN-1759118-B Diazepinoindole derivatives as kinase inhibitors PFIZER 2010-12-08 CN disclosed
US-7462713-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS, INC. (US) 2008-12-09 US disclosed
US-7462713-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS, INC. (US) 2008-12-09 US disclosed
EP-1947102-A1 Compositions comprising diazepinoindole derivatives as kinase inhibitors Pfizer, Inc. (US) 2008-07-23 EP disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070135415-A1 TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY AGOURON PHARMACEUTICALS, INC. 2007-06-14 US disclosed
US-20070135415-A1 TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY AGOURON PHARMACEUTICALS, INC. 2007-06-14 US disclosed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO disclosed
CN-1759118-A Diazepinoindole derivatives as kinase inhibitors PFIZER (US) 2006-04-12 CN disclosed
US-5863864-A REACTING CORRESPONDING BROMO- OR IODO-SUBSTITUTED SACCHARIN DERIVATIVES IN THE PRESENCE OF A PALLADIUM, NICKEL, COBALT OR RHODIUM TRANSITION METAL CATALYST AND OF A BASE WITH CARBON MONOXIDE AND WATER OR A C1-C6 ALCOHOL BASF AKTIENGESELLSCHAFT (DE) 1999-01-26 US disclosed
US-5744425-A POSTEMERGENCE, PREEMERGENCE HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-04-28 US disclosed
US-5723415-A AGRICULTURAL HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-03-03 US disclosed
US-5716905-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-02-10 US disclosed
US-5716906-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders MAP3K20, MAP3K3, MAP3K19 KMT2A 1591/4885SMN1; SMN2 3486/4885MAPT 2968/4885
US-20070135415-A1 TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY CHEK1, CHEK2, CHKA KMT2A 1951/4885SMN1; SMN2 3786/4885MAPT 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.